Wire Stories

Gold Resource Corporation Announces Q3 2023 Conference Call

DENVER--(BUSINESS WIRE)--Gold Resource Corporation (NYSE American: GORO) (the “Company”) will host a conference call Friday, November 3, 2023 at 10:00…

2 years ago

Polaris and OrionVM Partner to Next-Gen Cloud Transform Queensland ICT Market

OrionVM’s MicroPoP Technology Enables Leading Australian Data Centre to Uniquely Underpin Cloud Workloads, Including Enterprise Cloud, AI and Storage Solutions…

2 years ago

New Chinese Restrictions on Supply of Natural Graphite Will Negatively Impact Batteries Used in EV Market

Westwater Resources Offers Domestic Alternatives CENTENNIAL, Colo.--(BUSINESS WIRE)--Westwater Resources, Inc. (NYSE: American: WWR), an energy technology and battery-grade natural graphite…

2 years ago

Nanban Ventures Sends Letter Highlighting Steps Being Taken to Protect Investors

DALLAS--(BUSINESS WIRE)--Nanban Ventures LLC (“Nanban Ventures”), a Dallas-based venture capital firm investing in startups and other private companies that are…

2 years ago

Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor (TKI) at the European Society for Clinical Oncology (ESMO) Congress

BEIJING--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd. (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, announced preliminary…

2 years ago

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months…

2 years ago

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and…

2 years ago

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median…

2 years ago

athenahealth’s Annual ‘September is for Service’ Program Supports 50 Nonprofit Organizations Worldwide

Month-long campaign delivers more than $100,000 to nonprofit partners, with record employee participation BOSTON--(BUSINESS WIRE)--athenahealth, Inc., a leading provider of…

2 years ago

Edgecore Networks Introduces its New Wi-Fi 6 & Wi-Fi 6E Access Points for Mastering Every Terrain

Embracing Resilient Wi-Fi 6 & Wi-Fi 6E Connectivity with Edgecore Wi-Fi HSINCHU, Taiwan--(BUSINESS WIRE)--Edgecore Networks, a leading provider of traditional…

2 years ago